Dr. DiNardo's research focus is on analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr. DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients.
MD Anderson Cancer Center:
1515 Holcombe Blvd, Houston, TX 77030, USA
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life
AML stories, AML clinical trials, AML 101 articles and events with AML
Thanks to our HealthTree Community for AML Sponsors: